Loading clinical trials...
Loading clinical trials...
A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined With Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients With Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma With PD-L1 Expressing Tumors (PROPEL-36)
Conditions
Interventions
Bempegaldesleukin
Pembrolizumab
Locations
4
United States
Nebraska Methodist Hospital
Omaha, Nebraska, United States
Universitätsklinikum Salzburg, Landeskrankenhaus,
Salzburg, Salzburg Bundesland, Austria
Attikon University General Hospital
Athens, Attica, Greece
ASST Degli Spedali Civili di Brescia
Brescia, Lombardy, Italy
Start Date
March 9, 2022
Primary Completion Date
April 22, 2022
Completion Date
April 22, 2022
Last Updated
January 12, 2023
NCT05980000
NCT02358031
NCT03691714
NCT00088907
Lead Sponsor
Nektar Therapeutics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions